nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—Appetite absent—Metformin—polycystic ovary syndrome	0.0297	0.0635	CcSEcCtD
Olmesartan—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.0281	0.0601	CcSEcCtD
Olmesartan—Toothache—Metformin—polycystic ovary syndrome	0.0243	0.0519	CcSEcCtD
Olmesartan—Respiratory distress—Metformin—polycystic ovary syndrome	0.0233	0.0497	CcSEcCtD
Olmesartan—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.0182	0.039	CcSEcCtD
Olmesartan—Lightheadedness—Metformin—polycystic ovary syndrome	0.0132	0.0283	CcSEcCtD
Olmesartan—Injury—Metformin—polycystic ovary syndrome	0.0117	0.0249	CcSEcCtD
Olmesartan—Lethargy—Metformin—polycystic ovary syndrome	0.011	0.0234	CcSEcCtD
Olmesartan—Pain in extremity—Metformin—polycystic ovary syndrome	0.0107	0.0229	CcSEcCtD
Olmesartan—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.0096	0.0205	CcSEcCtD
Olmesartan—Influenza—Metformin—polycystic ovary syndrome	0.00927	0.0198	CcSEcCtD
Olmesartan—Pancreatitis—Metformin—polycystic ovary syndrome	0.00909	0.0194	CcSEcCtD
Olmesartan—Angina pectoris—Metformin—polycystic ovary syndrome	0.00903	0.0193	CcSEcCtD
Olmesartan—Neutropenia—Metformin—polycystic ovary syndrome	0.00867	0.0185	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00862	0.0184	CcSEcCtD
Olmesartan—Telmisartan—PPARG—polycystic ovary syndrome	0.00836	0.677	CrCbGaD
Olmesartan—Infestation NOS—Metformin—polycystic ovary syndrome	0.00827	0.0177	CcSEcCtD
Olmesartan—Infestation—Metformin—polycystic ovary syndrome	0.00827	0.0177	CcSEcCtD
Olmesartan—Rhinitis—Metformin—polycystic ovary syndrome	0.00744	0.0159	CcSEcCtD
Olmesartan—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00731	0.0156	CcSEcCtD
Olmesartan—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00729	0.0156	CcSEcCtD
Olmesartan—Angiopathy—Metformin—polycystic ovary syndrome	0.00674	0.0144	CcSEcCtD
Olmesartan—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00669	0.0143	CcSEcCtD
Olmesartan—SLCO1B3—pituitary gland—polycystic ovary syndrome	0.00663	0.138	CbGeAlD
Olmesartan—Malnutrition—Metformin—polycystic ovary syndrome	0.00646	0.0138	CcSEcCtD
Olmesartan—Muscle spasms—Metformin—polycystic ovary syndrome	0.00621	0.0133	CcSEcCtD
Olmesartan—Vision blurred—Metformin—polycystic ovary syndrome	0.00609	0.013	CcSEcCtD
Olmesartan—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.006	0.0128	CcSEcCtD
Olmesartan—Malaise—Metformin—polycystic ovary syndrome	0.00583	0.0124	CcSEcCtD
Olmesartan—Syncope—Metformin—polycystic ovary syndrome	0.0058	0.0124	CcSEcCtD
Olmesartan—Palpitations—Metformin—polycystic ovary syndrome	0.00571	0.0122	CcSEcCtD
Olmesartan—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00568	0.0121	CcSEcCtD
Olmesartan—Chest pain—Metformin—polycystic ovary syndrome	0.0055	0.0118	CcSEcCtD
Olmesartan—Myalgia—Metformin—polycystic ovary syndrome	0.0055	0.0118	CcSEcCtD
Olmesartan—SLCO1B3—vagina—polycystic ovary syndrome	0.00549	0.114	CbGeAlD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00546	0.0117	CcSEcCtD
Olmesartan—Discomfort—Metformin—polycystic ovary syndrome	0.00544	0.0116	CcSEcCtD
Olmesartan—Oedema—Metformin—polycystic ovary syndrome	0.00527	0.0113	CcSEcCtD
Olmesartan—Infection—Metformin—polycystic ovary syndrome	0.00524	0.0112	CcSEcCtD
Olmesartan—Shock—Metformin—polycystic ovary syndrome	0.00519	0.0111	CcSEcCtD
Olmesartan—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00517	0.011	CcSEcCtD
Olmesartan—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00516	0.011	CcSEcCtD
Olmesartan—SLCO1B3—endocrine gland—polycystic ovary syndrome	0.00513	0.107	CbGeAlD
Olmesartan—Skin disorder—Metformin—polycystic ovary syndrome	0.00512	0.0109	CcSEcCtD
Olmesartan—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.0051	0.0109	CcSEcCtD
Olmesartan—Anorexia—Metformin—polycystic ovary syndrome	0.00503	0.0107	CcSEcCtD
Olmesartan—AGTR1—adrenal cortex—polycystic ovary syndrome	0.00497	0.103	CbGeAlD
Olmesartan—Hypotension—Metformin—polycystic ovary syndrome	0.00493	0.0105	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00481	0.0103	CcSEcCtD
Olmesartan—Dyspepsia—Metformin—polycystic ovary syndrome	0.00464	0.00992	CcSEcCtD
Olmesartan—Decreased appetite—Metformin—polycystic ovary syndrome	0.00458	0.00979	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00455	0.00973	CcSEcCtD
Olmesartan—Fatigue—Metformin—polycystic ovary syndrome	0.00455	0.00971	CcSEcCtD
Olmesartan—Constipation—Metformin—polycystic ovary syndrome	0.00451	0.00963	CcSEcCtD
Olmesartan—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00435	0.00928	CcSEcCtD
Olmesartan—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00431	0.00921	CcSEcCtD
Olmesartan—Urticaria—Metformin—polycystic ovary syndrome	0.00419	0.00895	CcSEcCtD
Olmesartan—Abdominal pain—Metformin—polycystic ovary syndrome	0.00417	0.00891	CcSEcCtD
Olmesartan—AGTR1—pituitary gland—polycystic ovary syndrome	0.00402	0.0836	CbGeAlD
Olmesartan—AGTR1—adipose tissue—polycystic ovary syndrome	0.004	0.0832	CbGeAlD
Olmesartan—Losartan—ACE—polycystic ovary syndrome	0.00399	0.323	CrCbGaD
Olmesartan—Asthenia—Metformin—polycystic ovary syndrome	0.00378	0.00808	CcSEcCtD
Olmesartan—Pruritus—Metformin—polycystic ovary syndrome	0.00373	0.00797	CcSEcCtD
Olmesartan—Diarrhoea—Metformin—polycystic ovary syndrome	0.00361	0.00771	CcSEcCtD
Olmesartan—AGTR1—adrenal gland—polycystic ovary syndrome	0.00359	0.0747	CbGeAlD
Olmesartan—Dizziness—Metformin—polycystic ovary syndrome	0.00349	0.00745	CcSEcCtD
Olmesartan—Vomiting—Metformin—polycystic ovary syndrome	0.00335	0.00716	CcSEcCtD
Olmesartan—AGTR1—vagina—polycystic ovary syndrome	0.00333	0.0692	CbGeAlD
Olmesartan—Rash—Metformin—polycystic ovary syndrome	0.00333	0.0071	CcSEcCtD
Olmesartan—Dermatitis—Metformin—polycystic ovary syndrome	0.00332	0.0071	CcSEcCtD
Olmesartan—Headache—Metformin—polycystic ovary syndrome	0.0033	0.00706	CcSEcCtD
Olmesartan—Nausea—Metformin—polycystic ovary syndrome	0.00313	0.00669	CcSEcCtD
Olmesartan—AGTR1—endocrine gland—polycystic ovary syndrome	0.00311	0.0648	CbGeAlD
Olmesartan—SLCO1B1—endocrine gland—polycystic ovary syndrome	0.00297	0.0617	CbGeAlD
Olmesartan—ABCC2—adrenal gland—polycystic ovary syndrome	0.0026	0.054	CbGeAlD
Olmesartan—AGTR1—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00231	0.0049	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.00228	0.00484	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.00225	0.00477	CbGpPWpGaD
Olmesartan—ABCC2—endocrine gland—polycystic ovary syndrome	0.00225	0.0468	CbGeAlD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00222	0.00471	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00216	0.00459	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.0021	0.00445	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00204	0.00433	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00203	0.00431	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00202	0.00428	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00196	0.00415	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00193	0.0041	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.00193	0.00409	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—GHRL—polycystic ovary syndrome	0.0019	0.00404	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00189	0.00401	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.00188	0.00398	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.00187	0.00397	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	0.00178	0.00377	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	0.00178	0.00377	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.00176	0.00374	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00173	0.00367	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.00172	0.00366	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00169	0.00359	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.00169	0.00359	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00157	0.00332	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00155	0.00328	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.00151	0.00321	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	0.00149	0.00316	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00149	0.00316	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00147	0.00312	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00144	0.00305	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00142	0.00301	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00142	0.003	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	0.00141	0.003	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00139	0.00294	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00139	0.00294	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00138	0.00293	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	0.00135	0.00286	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—SLC2A4—polycystic ovary syndrome	0.00134	0.00284	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.00134	0.00284	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00132	0.00279	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00131	0.00277	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00131	0.00277	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00129	0.00273	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00128	0.00271	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.00126	0.00267	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—VEGFA—polycystic ovary syndrome	0.00125	0.00264	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00123	0.00262	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00122	0.00259	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.00121	0.00257	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	0.0012	0.00254	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	0.0012	0.00254	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00119	0.00252	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00119	0.00252	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00119	0.00252	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	0.00118	0.00251	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00115	0.00245	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.00115	0.00243	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.00114	0.00241	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00111	0.00235	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NMNAT3—polycystic ovary syndrome	0.0011	0.00232	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00108	0.00228	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00106	0.00224	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—NRG1—polycystic ovary syndrome	0.00105	0.00223	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00105	0.00223	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00105	0.00222	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.00105	0.00222	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.00102	0.00217	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—LPCAT2—polycystic ovary syndrome	0.001	0.00213	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SUOX—polycystic ovary syndrome	0.001	0.00213	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	0.001	0.00212	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.00099	0.0021	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.000983	0.00209	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.000972	0.00206	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.000961	0.00204	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.000956	0.00203	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.000953	0.00202	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	0.00095	0.00201	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ISYNA1—polycystic ovary syndrome	0.000932	0.00198	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.000911	0.00193	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	0.000906	0.00192	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.000874	0.00185	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.000868	0.00184	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.00085	0.0018	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.000842	0.00179	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NPB—polycystic ovary syndrome	0.00084	0.00178	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.000832	0.00176	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.000813	0.00172	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.000807	0.00171	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000804	0.00171	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000794	0.00168	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	0.000794	0.00168	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—AKR1C2—polycystic ovary syndrome	0.000792	0.00168	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TEAD2—polycystic ovary syndrome	0.000792	0.00168	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000779	0.00165	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.00077	0.00163	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000764	0.00162	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.000762	0.00162	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000759	0.00161	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000755	0.0016	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.00075	0.00159	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000746	0.00158	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000744	0.00158	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000738	0.00157	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NMNAT3—polycystic ovary syndrome	0.000736	0.00156	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000708	0.0015	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.000706	0.0015	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.000702	0.00149	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000701	0.00149	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000701	0.00149	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.000687	0.00146	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000675	0.00143	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—LPCAT2—polycystic ovary syndrome	0.000673	0.00143	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SUOX—polycystic ovary syndrome	0.000673	0.00143	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.000665	0.00141	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PNPLA2—polycystic ovary syndrome	0.000664	0.00141	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000659	0.0014	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.000656	0.00139	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000655	0.00139	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000636	0.00135	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SRD5A1—polycystic ovary syndrome	0.000629	0.00134	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ISYNA1—polycystic ovary syndrome	0.000626	0.00133	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000619	0.00131	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.000612	0.0013	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000603	0.00128	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—STAR—polycystic ovary syndrome	0.000601	0.00127	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.0006	0.00127	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	0.000594	0.00126	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.000571	0.00121	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000563	0.00119	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000549	0.00116	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.000542	0.00115	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HMMR—polycystic ovary syndrome	0.000535	0.00114	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AKR1C2—polycystic ovary syndrome	0.000532	0.00113	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TEAD2—polycystic ovary syndrome	0.000532	0.00113	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000513	0.00109	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.000512	0.00109	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HSD3B1—polycystic ovary syndrome	0.000511	0.00108	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.000505	0.00107	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	0.000505	0.00107	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.000504	0.00107	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.000504	0.00107	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000502	0.00107	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000499	0.00106	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000482	0.00102	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	0.000478	0.00101	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.000474	0.00101	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.00047	0.000996	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000469	0.000995	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—LHB—polycystic ovary syndrome	0.000466	0.000988	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FST—polycystic ovary syndrome	0.000457	0.00097	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HSD3B2—polycystic ovary syndrome	0.000455	0.000965	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000455	0.000964	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000452	0.000958	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000446	0.000946	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PNPLA2—polycystic ovary syndrome	0.000446	0.000946	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.000441	0.000935	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—AKR1C1—polycystic ovary syndrome	0.000441	0.000935	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000436	0.000925	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.000429	0.000911	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SRD5A1—polycystic ovary syndrome	0.000423	0.000897	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000422	0.000896	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000421	0.000894	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000418	0.000887	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000413	0.000876	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SULT2A1—polycystic ovary syndrome	0.000406	0.00086	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—STAR—polycystic ovary syndrome	0.000403	0.000856	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.000403	0.000856	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000399	0.000846	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	0.000399	0.000846	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—RRM2—polycystic ovary syndrome	0.000393	0.000833	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000392	0.000831	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000389	0.000825	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000387	0.000821	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000383	0.000812	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—YAP1—polycystic ovary syndrome	0.000379	0.000803	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NAMPT—polycystic ovary syndrome	0.000364	0.000772	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000363	0.00077	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	0.000362	0.000767	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.00036	0.000764	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HMMR—polycystic ovary syndrome	0.00036	0.000763	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP11A1—polycystic ovary syndrome	0.000359	0.000762	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000358	0.000759	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	0.000357	0.000757	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HSD3B1—polycystic ovary syndrome	0.000343	0.000728	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000342	0.000726	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—AKR1C3—polycystic ovary syndrome	0.000339	0.00072	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	0.000339	0.000719	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.000338	0.000718	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP17A1—polycystic ovary syndrome	0.000334	0.000709	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000325	0.00069	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	0.000321	0.000682	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.00032	0.000679	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000317	0.000672	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—LHB—polycystic ovary syndrome	0.000313	0.000664	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HSD3B2—polycystic ovary syndrome	0.000306	0.000649	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AKR1C1—polycystic ovary syndrome	0.000296	0.000628	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000295	0.000625	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000295	0.000625	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TH—polycystic ovary syndrome	0.000289	0.000613	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000284	0.000602	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—SLC2A4—polycystic ovary syndrome	0.000281	0.000596	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000281	0.000596	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000274	0.000581	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000273	0.000579	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SULT2A1—polycystic ovary syndrome	0.000273	0.000578	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP19A1—polycystic ovary syndrome	0.000264	0.000561	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—RRM2—polycystic ovary syndrome	0.000264	0.00056	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000259	0.00055	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000258	0.000547	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000257	0.000545	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—YAP1—polycystic ovary syndrome	0.000254	0.00054	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000248	0.000525	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NAMPT—polycystic ovary syndrome	0.000244	0.000519	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000244	0.000517	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	0.000243	0.000515	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP11A1—polycystic ovary syndrome	0.000241	0.000512	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	0.00024	0.000508	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GNAS—polycystic ovary syndrome	0.000236	0.0005	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AKR1C3—polycystic ovary syndrome	0.000228	0.000484	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000226	0.00048	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NCOR1—polycystic ovary syndrome	0.000225	0.000477	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP17A1—polycystic ovary syndrome	0.000224	0.000476	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000215	0.000457	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP1A1—polycystic ovary syndrome	0.000213	0.000452	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000211	0.000448	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—MTHFR—polycystic ovary syndrome	0.000199	0.000421	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TH—polycystic ovary syndrome	0.000194	0.000412	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—SLC2A4—polycystic ovary syndrome	0.000189	0.000401	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000181	0.000384	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP19A1—polycystic ovary syndrome	0.000178	0.000377	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LEP—polycystic ovary syndrome	0.000177	0.000376	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PPARG—polycystic ovary syndrome	0.000161	0.000342	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—POMC—polycystic ovary syndrome	0.000159	0.000337	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GNAS—polycystic ovary syndrome	0.000159	0.000336	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000158	0.000335	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—INS—polycystic ovary syndrome	0.000158	0.000335	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000152	0.000323	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—INS—polycystic ovary syndrome	0.000151	0.000321	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NCOR1—polycystic ovary syndrome	0.000151	0.00032	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000146	0.000311	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000146	0.00031	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP1A1—polycystic ovary syndrome	0.000143	0.000304	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000139	0.000295	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—MTHFR—polycystic ovary syndrome	0.000133	0.000283	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000112	0.000238	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PPARG—polycystic ovary syndrome	0.000108	0.00023	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—POMC—polycystic ovary syndrome	0.000107	0.000226	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—INS—polycystic ovary syndrome	0.000106	0.000225	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	9.57e-05	0.000203	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6—polycystic ovary syndrome	6.62e-05	0.00014	CbGpPWpGaD
